Vanda Pharmaceuticals (NASDAQ: VNDA) announced positive topline results from its randomized controlled clinical study evaluating tradipitant, an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of nausea and vomiting induced by GLP-1 receptor agonist Wegovy in overweight and obese adults.
This study, which pre-treated patients with either tradipitant or placebo before administering a 1 mg injection of Wegovy, a dose that normally takes nine weeks of titration to reach, succeeded and met its primary endpoint, with only 29.3% of tradipitant-treated participants (17/58) experiencing vomiting compared to 58.6% on placebo (34/58) (p=0.0016), representing a 50% relative reduction.
Tradipitant demonstrated a favorable safety profile consistent with previous studies with no new safety signals observed.
In a statement, Mihael H. Polymeropoulos, MD, president, CEO and Chairman of Vanda, commented, “These results demonstrate tradipitant’s potential to mitigate GLP-1 induced nausea and vomiting which are key contributors of the 30-50% real-world discontinuation rates for GLP-1 agonists, often before therapeutic doses are reached. Tradipitant’s effect in reducing nausea and vomiting could significantly improve GLP-1 agonist adherence enabling more people to receive the full therapeutic benefit.”
